The mechanisms whereby growth hormone may increase renal plasma flow (RPF) and GFR are not known, but circumstantial evidence has implicated insulin-like growth factor I (IGF-I) as a -mediator of this effect. This study examined whether an infusion of IGF-I will increase RPF and GFR, whether this effect occurs quickly, and if this effect is dependent on eicosanoids or peptide hormones known to affect renal function. Rats fasted for 3 d to reduce IGF-I and IGF-I plasma binding proteins were anesthetized; then the rats received an intravenous injection of 25 Mg/kg IGF-I, and an infusion of 25 ;Lg/kg IGF-I within 20 min. Controls received infusion of the vehicle. RPF (para-aminohippurate clearances), GFR (inulin clearances), renal vascular resistance (RVR), mean arterial blood pressure (MABP), plasma IGF-I, and glucose concentrations were measured repeatedly. At the end of the 20-min infusion, plasma IGF-I tended to be increased in the animals that received IGF-I (P = 0.069), but did not increase in the control rats. IGF-I induced a significant and sustained fall in RVR and rise in RPF and GFR without any change in MABP. A small, transient, but significant decrease in plasma glucose concentrations was observed during IGF-I but not during vehicle infusion. Indomethacin, but not somatostatin, blocked the renal response to IGF-I infusion. Thus, IGF-I infusion increases RPF and GFR and reduces RVR in fasted rats. This effect requires the presence of eicosanoids but does not seem to require other peptide hormones suppressed by somatostatin.
Introduction
There is abundant evidence that growth hormone increases renal plasma flow rate (RPF)' and GFR in humans (1) . Patients with acromegaly and elevated circulating growth hor- 1 . Abbreviations used in this paper: HCT, hematocrit; IGF, insulin-like growth factor; MABP, mean arterial blood pressure; PAH, para-aminohippurate; RPF, renal plasma flow rate; RVR, renal vascular resistance. mone levels have increased RPF and GFR (2) . After pituitary ablation, RPF and GFR fall to normal; this fall precedes the reduction in kidney size (2) . Moreover, injections of growth hormone in man increase RPF and GFR. However, the elevation in RPF and GFR does not occur for at least several hours after the injection (3, 4) . These findings suggest that growth hormone may increase RPF and GFR by stimulating the release of one or more mediators.
Several lines of evidence suggest that insulin-like growth factor-I (IGF-I) may be one such mediator. First, growth hormone stimulates the secretion of IGF-I in the kidney and other organs and causes a rise in plasma IGF-I. Second, the increase in plasma IGF-I after growth hormone injection only occurs after several hours, at approximately the same time that RPF and GFR rise (3, 4) . Moreover, after growth hormone injection, the elevations in RPF, GFR, and plasma IGF-I persist at a time when plasma growth hormone has decreased to baseline values (3) . Third, in cases of growth hormone deficiency or excess, RPF, GFR, and plasma IGF-I co-vary in the same direction (i.e., all are reduced or increased) (3, 4) . Fourth, IGF-I receptors have been identified in the kidney (5) .
Although the foregoing studies demonstrate a temporal relationship between elevations in IGF-I, renal hemodynamics, and growth hormone, they do not prove that IGF-I causes the increase in RPF and GFR. Studies therefore were undertaken to test more directly the following questions: (a) Does an intravenous infusion of IGF-I increase RPF and GFR in rats? (b . At the conclusion of the study, blood samples were obtained simultaneously from the left renal vein and femoral artery to determine the renal extraction of PAH, which was considered to be constant throughout the procedure in each animal. After the above procedures, the following studies were carried out. Study 1. After a 75-105-min equilibration period, eight male Sprague-Dawley rats, weighing 246±7 (SEM) g, underwent 12 20-min urine clearance periods. The first two clearance periods were designated as baseline. At the beginning of the third period, the rats were given an intravenous injection of 25 lAg/kg IGF-I in 0.2 ml of normal saline over -45 seconds. This was followed by a continuous infusion of 25 ,g/kg IGF-I in 0.3 ml of normal saline; the total time for bolus injection and continuous infusion of IGF-I was 20 min, which was the duration of the third clearance period. Seven Sprague-Dawley rats, weighing 251±6 g, served as controls. These animals were treated in an identical fashion except that they received the same quantity of acetic acid diluted in normal saline as vehicle instead of the IGF-I solution. Before and at the end ofthe IGF-I or vehicle infusion, 200 1A ofarterial blood were withdrawn for measurement of plasma IGF-I and glucose. At the midpoint ofeach ofthe 12 clearance periods, -70 Ml ofarterial blood were collected in heparinized capillary tubes for determining the hematocrit and plasma concentrations of inulin and PAH.
The IGF-I used is a recombinant DNA-derived human IGF-I analogue (generously provided by Dr. Kathrine Fagin, Amgen, Thousand Oaks, CA). Its amino acid sequence differs from human IGF-I only in position 59, at which threonine was substituted for methionine. The peptide was dissolved in 0.1 M acetic acid to form a stock solution in a concentration of I mg/ml. This solution was further diluted with normal saline for the infusion studies. Study 2. The following six groups of male Munich Wistar rats were studied: groups la, 2a, and 3a received IGF-I injections and infusions as indicated in study 1; their body weights were 254±22, 218±4, and 205±6 g, respectively.. Groups lb, 2b, and 3b received the vehicle infusion as described for study 1; their body weights were 260± 10, 211±6, and 217±6 g, respectively. Groups 2a and 2b received a constant infusion of indomethacin, 2.5 mg/kg/h (Sigma Chemical Co., St. Louis, MO). A stock solution of indomethacin, 3.57 mg/ml, with sodium carbonate anhydrous, 114 mg/ml was added to the Ringer's lactate solution (groups 2a and 2b) containing the radioactive PAH and inulin. Groups 3a and 3b were infused continuously with 2.5,ug/h somatostatin (SRIF) (Sigma Chemical Co.). This dose of SRIF has been demonstrated to block the release of several peptide hormones, including glucagon, growth hormone, and insulin (7). The SRIF was added to the PAH and inulin solution. Thus, there was no difference in the volumes infused in any of the six groups in study 2. The inulin, PAH, and indomethacin or somatostatin infusions were given for 200 min, from the beginning ofa 120-min equilibration period until the end of four 20-min urine clearance periods. After the first 80 min of equilibration, 25 ug/kg IGF-I or vehicle was given as a bolus injection, followed by a continuous infusion of25 Mg/kg IGF-I or vehicle. As in Study 1, the duration of time for the bolus injection and continuous infusion was 20 min. Note that there was an interval of 20 min between the end ofthe IGF-I or vehicle infusion and the first urine collection period. Thus, study 2 was designed to shorten the period during which the rats were anesthetized to -230 min and yet to allow the animals sufficient time to respond to the compounds administered. Plasma was obtained for measurement of glucose before, at the midpoint (i.e., 10 min after the IGF-I or vehicle injection), and at the end of the infusion of IGF-I or vehicle. At 
Results
Study 1. RPF and GFR at baseline were not different in the two groups of rats. The grand means (microliters per minute per 100 grams) for baseline RPF in the IGF-I-treated and control rats were 2,459±133 (SEM) and 2,801+79, respectively (Fig. 1) . The grand means for GFR (microliters per minute per 100 grams) at baseline were 720±28 and 768±24 in the IGF-I treated and control groups, RPF and GFR both appeared to rise during the 20 min that IGF-I was administered and became significantly greater than baseline during the first 20 min after cessation of the infusion (Fig. 1) . These values remained elevated above baseline throughout the first five 20-min clearance periods after the infusion. The maximum values for RPF and GFR were observed during the fourth and third clearance periods, respectively, after the IGF-I infusion, and were 3,247±103 (P < 0.05 vs. baseline) and 898±43 (P < 0.05) ,ul/min/100 g. Thereafter, both RPF and GFR began to fall toward baseline. The maximum percent increase above baseline values for RPF and GFR in the IGF-I-treated rats was 29.9±3.2 (P < 0.05) and 24.7±2.9% (P < 0.05), respectively.
In the control rats, there were no changes in RPF or GFR during the study (Fig. 1) . RPF was significantly greater in the IGF-I-treated versus control rats during the second and third periods after the IGF-I infusion. Similarly, GFR was significantly greater in the IGF-I treated versus control rats during the fourth and fifth periods after the infusion.
RVR during baseline was similar in the IGF-I-and vehicle-treated rats (Fig. 1) ; the grand means (millimeters of mercury Al/min per 100 grams) were 0.023±0.002 and 0.022±0.002, respectively. RVR began to fall during the IGF-I infusion and was significantly below baseline for the first five periods after the infusion. The lowest RVR occurred during the third clearance period after finishing the IGF-I infusion and was 0.017±0.001 mmHg Al/min per 100 g. This constituted a 26.1±3.9% decrease below baseline (P < 0.05). RVR was significantly lower in IGF-I treated rats as compared with controls during the second and third clearance periods after the IGF-I or vehicle infusion.
The grand mean for the filtration fraction in the experi- Fig. 2 ).
the IGF-I or vehicle infusion. Bars indicate SEM. The percent changes in RPF, GFR, and RVR in the IGF-I eline, P < 0.05. tDifferent from control, P < 0.05. vs. control rats in Groups 1 a and lb were similar to the percent changes in these parameters in the animals given SRIF (i.e., rol rats during baseline was 0.30±0.01 and groups 3a vs. 3b). However, both the IGF-I-and vehicletively (P = NS, Fig. 1 ). The grand mean for treated rats given SRIF (groups 3a and 3b) tended to have a seline in the IGF-I-treated and control rats lower RPF and GFR in comparison to the rats not given SRIF 19±6 mmHg, respectively (P = NS). Neither (groups la and Ib) ( Table I ). The MABP, filtration fraction, nor MABP changed in either group during and hematocrit were not different in any of the six groups nT also did not vary between the two groups. (Table I, Fig. 2 (Fig. 1) mones including renin, insulin, glucagon, and growth horran the control rats that did not receive indomone (7, 14) . A rise in plasma glucagon and growth hormone in, P < 0.05. The comparisons were made concentrations can increase RPF and GFR and lower RVR; ens obtained at the same time of the infusion this effect occurs acutely with glucagon and is delayed for several hours with growth hormone (3, 15) . Injection of IGF-I may increase plasma glucagon and growth hormone and reduce insulin, probably due to the IGF-I induced decrease in plasma glucose (16) (Table II) . Therefore, it seemed important to exclude the possibility that a rise in glucagon or growth hormone levels could have increased the renal hemodynamics after IGF-I infusion. In this study, infusion of SRIF did not impair the IGF-I-induced rise in RPF and GFR and fall in RVR. This finding suggests that the IGF-I induced rise in renal hemodynamics is independent of a number of peptide hormones including insulin, glucagon, and growth hormone.
The rats infused with SRIF and vehicle (group 3b) tended to have lower RPF and GFR and higher RVR as compared with the animals not infused with SRIF (group lb). SRIF may lower GFR in healthy man (17) . This effect of SRIF might be due to the suppression of one or more peptide hormones that act on the kidney.
IGF-I is synthesized in many tissues including the kidney (18). Some investigators suggest that IGF-I acts locally where it is synthesized, as an autacoid, and that plasma IGF-I does not play a physiological role (18, 19) . This study, however, provides evidence that systemic infusion and changes in plasma levels of IGF-I can affect renal function.
This study also suggests that IGF-I may play a role in the regulation of renal function. The evidence is that IGF-I infusion increases RPF and GFR and reduces RVR. Moreover, two commonly occurring phenomena that alter plasma IGF-I levels, growth hormone administration and nutritional intake, also affect renal function (1, 3, 11, 12, 20) . Further studies are clearly needed to examine the role of IGF-I in the regulation of renal function, particularly in malnutrition.
